Slide 1: … just getting started: First quarter 2019
… just getting started First quarter 2019 Evotec SE, First Quarter 2019 Results, 14 May 2019
Slide 2: Forward-looking statement
Forward-looking statement Information set forth in this presentation contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this presentation. Such forward-looking sta
Slide 3: Welcome to Q1 2019 – The Management Team
Welcome to Q1 2019 The Management Team Werner Lanthaler Enno Spillner Craig Johnstone Cord Dohrmann CEO1) CFO1) COO1) CSO1) PAGE 2 1) On the call for Q1 2019 results
Slide 4: Agenda
Agenda Highlights Q1 & Strategy Financial performance Scientific and operational performance Guidance & Next steps PAGE 3
Slide 5: Very good scientific and operational progress
Very good scientific and operational progress Q1 2019 – State of play Multiple new and extended drug discovery and development agreements Important milestone achievements, good progress with co-owned pipeline Licence agreement with Galapagos in fibrosis Agreement with The Mark Foundation in
Slide 6: Strong start and good underlying indications for '19
Strong start and good underlying indications for ´19 Financials Q1 2019 & FY 2019 Guidance Strong financial performance Guidance 2019 confirmed Group revenues from contracts with Approx. 10% growth in Group revenues customers up 27% to € 103.8 m from contracts with customers without (Q1 2018: €
Slide 7: All moves follow consistent long-term strategy
All moves follow consistent long-term strategy “Action Plan 2022 – Leading External Innovation” 2022 Today 2018 2012 2009 PAGE 6
Slide 8: Agenda
Agenda Highlights Q1 & Strategy Financial performance Scientific and operational performance Guidance & Next steps PAGE 7
Slide 9: Strong base business and important milestones
Strong base business and important milestones Condensed income statement Q1 2019 – Evotec SE and subsidiaries in € m1) Revenue growth mainly due Q1 2019 Q1 2018 % vs 2018 to strong performance in base business and Revenues from contracts with milestone contributions 103.8 81.6 27% customers2) Gr
Slide 10: Continued growth path at strong margin
Continued growth path at strong margin Revenues & Gross margin overview Revenues from contracts with Gross margin1) Revenue growth due to strong customers (in € m) (in %) performance in base business and positive milestone Base revenues Total Margin Milestones/upfronts/licences Margin excl. contri
Slide 11: Both segments fully on strategy
Both segments fully on strategy Segment information Q1 2019 – Evotec SE and subsidiaries in € m1) Inter- EVT EVT segment Not Evotec Revenue growth in Execute Innovate elimination allocated2) Group EVT Execute driven by strong performance in Revenues 100.3 18.8 (18.8) 3.5 103.8 the base business
Slide 12: Relevant impact of new IFRS 16 on balance sheet
Relevant impact of new IFRS 16 on balance sheet Balance sheet and liquidity – 31 March 2019 versus 31 December 2018 Balance sheet total € 880.8 m (31 December 2018: € 771.9 m without IFRS 16) Increase in property, plant and equipment following capitalisation of operating leases as fixed assets (
Slide 13: Agenda
Agenda Highlights Q1 & Strategy Financial performance Scientific and operational performance Guidance & Next steps PAGE 12
Slide 14: ONE fully integrated platform
ONE fully integrated platform Unique business model PAGE 13
Slide 15: Operational for our > 200 partners: EVT Execute
Operational for our > 200 partners EVT Execute – Major achievements Q1 2019 Multiple new drug discovery and development agreements Excellent scientific progress driving expansion of existing partnerships Strong business performance and efficiency improvements across all business lines and site
Slide 16: Strong and well-balanced global customer mix
Strong and well-balanced global customer mix EVT Execute – Selected KPIs Q1 2019 Revenues by customer Customer type ytd1) Revenues by region ytd1) segment ytd1) (in %) (in %) (in %) 100% 100% 100% Mid-sized RoW 17% 3% Pharma Remaining 33% Foun- 6% USA 36% dations Top 11-30 20% customers Biotech 46%
Slide 17: Acceleration of science across various ventures
Acceleration of science across various ventures EVT Innovate – Major achievements Q1 2019 Good pipeline progress, e.g. with Phase II in Chronic Cough (Bayer) Licence agreement with Galapagos in fibrosis Driving anti-infective innovation through alliances with Helmholtz and GARDP1) Strategic
Slide 18: Strong progress in fully invested pipeline
Strong progress in fully invested pipeline Partnership portfolio – Highlights in Q1 2019 marked in green Molecule Therapeutic Area/Indication Partner Discovery Pre-clinical Phase I Phase II EVT201 CNS – Insomnia BAY-1817080 Chronic cough ND1) Chronic cough Ph. II start SGM-10192) Inflammation (NASH)
Slide 19: Re-defining DD paradigm from patient to patient
Re-defining DD paradigm from patient to patient Game-changing platforms for better translation Translational Holistic Superior Models Profiles Knowledge iPSC PanOmics AI & ML platform platform platform1) PAGE 18 1) Artificial Intelligence & Machine Learning
Slide 20: Precision medicine … just the beginning
Precision medicine … just the beginning Evotec and Indivumed in colorectal cancer (CRC)1) Colorectal Cancer (CRC) a major cancer indication & Third most common cancer type Following lung and breast cancer 8% of the global cancer incidence Precision medicine collaboration to deliver Market
Slide 21: World-leading in nephrology… just the beginning
World-leading in nephrology… just the beginning NURTuRE – Kidney disease processes, platforms and networks Biomarker & stratification Disease-affected cell type Patient data Human kidney- and samples on-a-chip Disease- specific Patient drugs Clinical Centers “The anonymised data contained within the
Slide 22: Patient-derived iPSC assays as new gold standard
Patient-derived iPSC assays as new gold standard World-leading iPSC processes and network “IPS cells can become a powerful tool to develop new drugs to cure intractable diseases because they can be made from patients’ somatic cells.” Shinya Yamanaka, Nobel prize laureate Disease-specific drugs Scree
Slide 23: Agenda
Agenda Highlights Q1 & Strategy Financial performance Scientific and operational performance Guidance & Next steps PAGE 22
Slide 24: Strong year ahead – Guidance 2019 confirmed
Strong year ahead – Guidance 2019 confirmed Guidance 2019 Double- Approx. 10% growth in Group revenues from contracts with customers 1 digit top- without revenues from recharges1) line growth Profitable Adjusted Group EBITDA2) expected to improve by approx. 10% 2 and growing compared to € 92.0 m
Slide 25: Important next dates: Financial calendar 2019
Important next dates Financial calendar 2019 Annual Report 2018 28 March 2019 Quarterly Statement Q1 2019 14 May 2019 Annual General Meeting 2019 19 June 2019 Half-year 2019 Interim Report 14 August 2019 Quarterly Statement 9M 2019 12 November 2019 PAGE 24
Slide 26: HRESEARCHNEVE
HRESEARCHNEVE ASTOPS
Slide 27: Your contact: Dr Werner Lanthaler
Your contact: Dr Werner Lanthaler Chief Executive Officer +49.(0).40.560 81-242 +49.(0).40.560 81-333 Fax werner.lanthaler@evotec.com